Fig 6 - by Takafumi Kabuto (14797727)

Table_1_Soil Properties Interacting With Microbial Metagenome in Decreasing CH4 Emission From Seasonally Flooded Marshland Following Different Stages of Afforestation.xlsx by Qian Zhang (49333)

“…Both abundances of mcrA and pmoA genes decreased significantly with increasing plantation age. …”

Impact of breastfeeding duration on T-lymphocyte subsets at 6 months of age. by Michelle A. E. Jansen (740955)

<i>dcerk¹</i> mutants show decreased mitochondrial oxidative phosphorylation, lower ATP level, and increased glycolysis compared to control flies. by Niraj K. Nirala (424266)

Expression of miR-24 target Trib3 impairs hematopoietic development of ESCs. by Lynn Roy (687524)

“…<b>D)</b> Three independent infections were performed and the average percent of CD41+ HPCs observed is shown. The decrease in CD41+ cells induced by Trib3 expression is significant with a P value of <0.001.…”

PCAIs disrupt actin filaments in NCI-H23 cells. by Matthew D. Gregory (19929096)

T2 LCLs have less IRF4 (Cluster 9) and more NFATc1 (Cluster 10) compared to latent cells, or T1 cells in Cluster 9. A. by Jillian A. Bristol (5566289)

Muscimol-induced inactivation of the VPM. by Carlos Castejon (2182382)

PCAIs suppress and disrupt the levels of vinculin punctates in NCI-H23 cells. by Matthew D. Gregory (19929096)

Highly Stable Polyoxovanadate-Based Zn–MOF with Dual Active Sites as a Solvent-free Catalyst for C–C Bond Formation by Hongrui Tian (6493886)

“…A polyoxovanadate-based zinc–organic framework, [Zn­(bix)]­{V₂O₆}­(V-Zn-MOF, bix = 1,4-bis­(imidazole-1-ylmethyl)­benzene), was successfully synthesized under hydrothermal conditions. …”

<i>P2RX7</i> ablation improves <i>mdx</i> muscle strength and endurance and object recognition memory and decreases anxiety in vivo. by Anthony Sinadinos (694160)

Representative CEUS images with BR55 of mice with a subcutaneous tumour allograft (arrows) under treatment. by Felix L. Herr (21544362)

Evolution of spiking behavior as a function of number of inputs in input encoding for a given stimuli pattern. by Evan Cudone (5768813)

Decreased CD4^pos iNKT cell numbers in the peripheral organs of T cell-specific <i>Gfi1</i>-deficient mice. by Toshiaki Yasuoka (2827457)

Anisotropic Contraction of a Polyaromatic Capsule and Its Cavity-Induced Compression Effect by Natsuki Kishida (8850218)

“…The resultant capsule, composed of two metal ions and four <i>ortho</i>-substituted ligands, possesses a spheroidal cavity (1.1 nm × 1.5 nm × 1.5 nm) fully encircled by a polyaromatic framework. …”

Reactive Oxygen Species Suppress Cardiac Na_V1.5 Expression through Foxo1 by Weike Mao (181121)

“…Foxo1 mutant (T24A/S319A-GFP, Foxo1-AA-GFP) was retained in nuclei, leading to a decrease of Na_V1.5 expression and Na⁺ current, while silencing of Foxo1 expression by RNAi resulted in the augmentation of Na_V1.5 expression. …”

S4 Fig - by R. J. S. D. Heine (17889199)

“…Cost-based pricing models are discussed as a possibility for cost containment. This study focuses on two drugs, pembrolizumab (Keytruda) and daratumumab (Darzalex), to explore the potential effect of indication broadening on the estimated price when using the cost-based pricing (CBP) model proposed by Uyl-de Groot and Löwenberg (2018).…”

S1 Fig - by R. J. S. D. Heine (17889199)

“…Cost-based pricing models are discussed as a possibility for cost containment. This study focuses on two drugs, pembrolizumab (Keytruda) and daratumumab (Darzalex), to explore the potential effect of indication broadening on the estimated price when using the cost-based pricing (CBP) model proposed by Uyl-de Groot and Löwenberg (2018).…”

S3 Fig - by R. J. S. D. Heine (17889199)

“…Cost-based pricing models are discussed as a possibility for cost containment. This study focuses on two drugs, pembrolizumab (Keytruda) and daratumumab (Darzalex), to explore the potential effect of indication broadening on the estimated price when using the cost-based pricing (CBP) model proposed by Uyl-de Groot and Löwenberg (2018).…”

S6 Fig - by R. J. S. D. Heine (17889199)

“…Cost-based pricing models are discussed as a possibility for cost containment. This study focuses on two drugs, pembrolizumab (Keytruda) and daratumumab (Darzalex), to explore the potential effect of indication broadening on the estimated price when using the cost-based pricing (CBP) model proposed by Uyl-de Groot and Löwenberg (2018).…”